Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Sprint Bioscience AB

Market Cap 463M 48.38M 42.2M 38.9M 36.59M 68.37M 4.57B 68.97M 179M 2.24B 182M 178M 7.87B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 463M 48.38M 42.2M 38.9M 36.59M 68.37M 4.57B 68.97M 179M 2.24B 182M 178M 7.87B EV / Sales 2026 *
5.46x
EV / Sales 2027 * 2.99x
Free-Float
64.78%
Yield 2026 *
-
Yield 2027 * -
1 day+0.46%
1 week+19.29%
Current month+26.51%
1 month+21.27%
3 months+106.10%
6 months+203.81%
Current year+198.64%
1 week 3.6
Extreme 3.6
4.48
1 month 3.16
Extreme 3.16
4.48
Current year 1.36
Extreme 1.355
4.48
1 year 0.42
Extreme 0.42
4.48
3 years 0.36
Extreme 0.36
4.48
5 years 0.36
Extreme 0.36
9.6
10 years 0.36
Extreme 0.36
59.5
Manager TitleAgeSince
Chief Executive Officer 42 30/09/2023
Chief Tech/Sci/R&D Officer 55 31/12/2008
Director of Finance/CFO 55 03/05/2026
Director TitleAgeSince
Chairman 70 31/12/2009
Director/Board Member 50 31/12/2018
Chairman 58 31/12/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.46%+19.29%+838.03%+689.57% 49.06M
-2.23%-0.03%+61.34%+109.10% 56.24B
+4.60%+5.85%+54.47%+43.04% 43.76B
-1.44%+5.50%-13.41%-19.24% 23.32B
-2.69%+4.27%-4.47%+379.00% 21.34B
+3.22%+3.77%+19.92%-35.05% 15.75B
-0.67%+1.18%+12.91%-39.22% 15.6B
-1.01%-1.27%+25.52%+171.92% 13.18B
+3.07%+3.59%+25.54% - 12.01B
+4.95%+7.51%+123.21%+249.05% 11.87B
Average +0.83%+5.26%+114.31%+172.02% 21.31B
Weighted average by Cap. +0.50%+3.55%+37.95%+98.21%

Financials

2026 *2027 *
Net sales 84.8M 8.86M 7.72M 7.12M 6.7M 12.52M 836M 12.63M 32.85M 411M 33.24M 32.53M 1.44B 155M 16.19M 14.12M 13.02M 12.24M 22.88M 1.53B 23.08M 60.05M 751M 60.76M 59.46M 2.63B
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
30
Date Price Change Volume
18/06/26 4.390 kr +0.46% 455,260
17/06/26 4.370 kr +1.16% 365,770
16/06/26 4.320 kr +4.85% 860,140
15/06/26 4.120 kr +11.96% 915,212
12/06/26 3.680 kr -2.39% 361,710

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRINT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!